The hypermethylation of p16, as a tumor suppressor, was demonstrated to make contribution to the clinical treatment and may be used as a biomarker for early diagnosis of NSCLC (189, 190). This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.